LOX and cancer: BPAN suppresses LOX effects in vivo and in vitro.161 In addition, LOX expression is correlated with elevated VEGF and platelet-derived growth factor expression, and both were downregulated by β-aminopropionitrile in vivo.162 CCT365623, another LOX inhibitor, disrupts EGFR cell surface retention and slows in vivo primary and metastatic tumor progression.163 Even though these LOX inhibitors have not been introduced in clinical trials for cancer therapy, they are promising therapeutic options for premetastatic niche disruption after surgery.